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See Article, pages 832–838Hepatitis C virus (HCV) RNA quantiﬁcation was made possible by
means of standardized, commercial assays in the early to mid-
1990s [1]. These assays were broadly used in both retrospective
and prospective cohort studies and clinical trials. They showed
that, in contrast to, for instance, human immunodeﬁciency virus
infection, the HCV RNA level has no prognostic value on the nat-
ural outcome of HCV-related liver disease. By contrast, monitor-
ing of HCV RNA levels was shown to be crucial to assess the
response to antiviral therapy and tailor treatment to it [2]. The
concept of ‘‘response-guided therapy” emerged when it was
demonstrated that the early on-treatment viral kinetics were
more strongly related to the ﬁnal outcome of therapy than any
pre-therapeutic parameter.
Different time points were considered key to assess the on-
treatment virological response to pegylated interferon (IFN)-a
and ribavirin therapy. Initially, week 12 was used as a decision
time point to stop therapy in patients who did not achieve a 2-
log decrease or more in HCV RNA level relative to baseline, or
an undetectable HCV RNA at this time point. Indeed, the likeli-
hood of a sustained virological response (SVR) in these patients,
if treatment was continued, was less than 2% [3,4]. More recently,
week 4 was used to classify the patients who responded by a
more than a 2-log drop at week 12 into three groups: (1) patients
with undetectable HCV RNA at week 4 (rapid virological
response, RVR) (2) patients with detectable HCV RNA at week 4
but undetectable HCV RNA at week 12 (early virological response
[EVR] for some, complete early virological response [cEVR] for
others) (3) patients with detectable HCV RNA at week 12 in spite
of a more than 2-log drop at this time point (slow virological
response for some, partial early virological response [pEVR] for
others). Week 24 is sometimes used to further subclassify slow
virological responders into those who achieve undetectable
HCV RNA at this time point, and those who do not.
Common guidelines, for response-guided HCV therapy with
pegylated IFN-a and ribavirin, recommend the treatment of rapid
virological responders for 24 weeks if they have a low baseline
HCV RNA level (<400,000-800,000 IU/ml according to the study);Journal of Hepatology 20
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slow (or partial early) virological responders for 72 weeks if their
HCV RNA is undetectable at week 24 [5–8]. These recommenda-
tions most likely apply whatever the HCV genotype. Shorter than
24 week therapy, in patients infected with genotypes 2 and 3
who achieve an RVR, remains controversial, as conﬂicting results
have been reported [9–11].
As most of these treatment decisions are based on undetect-
able HCV RNA levels at different time points, the lower limit of
detection of commercial HCV RNA assays has become critical.
Early quantitative assays, based on the branched DNA technology
or classical competitive polymerase chain reaction (PCR), were
poorly sensitive. Thus, non-quantitative, qualitative assays had
to be used to detect small amounts of HCV RNA, and viremia
was considered undetectable below the lower limit of detection
of these assays [12]. The Cobas Amplicor™ assay (Roche Molecu-
lar Systems, Pleasanton, California) dominated the market for
many years and, after standardization of HCV RNA quantiﬁcation
units was achieved, its lower limit of detection was found to be
50 international units (IU)/ml. Therefore, as this assay was used
in most, if not all of the clinical trials run with pegylated IFN-a
and ribavirin, an ‘‘undetectable HCV RNA” in fact corresponded
to an HCV RNA level below 50 IU/ml at the different time points.
Major progress has been made in the technology used to
quantify viral genomes. Nowadays, most laboratories use real-
time PCR-based methods. In theory, these methods provide bet-
ter analytical sensitivity, broader dynamic ranges of quantiﬁca-
tion, improved speciﬁcity, precision and reproducibility, and
offer opportunities for high throughput and automation [13].
Two real-time PCR platforms are currently available for detection
and quantiﬁcation of HCV RNA: the Cobas Taqman (CTM) plat-
form, which can be used together with automated sample prep-
aration with the Cobas AmpliPrep device (CAP–CTM, Roche
Molecular Systems); and the Abbott platform (Abbott Molecular,
Des Plaines, Illinois), which uses the m2000RT ampliﬁcation plat-
form together with the m2000SP device for sample preparation.
CAP–CTM has been reported to underestimate HCV RNA levels
in approximately 15% of HCV genotype 2 and 30% of HCV geno-
type 4 samples, essentially due to nucleotide mismatches with
the primers and probes used [14,15]. A newer, improved version
of this assay will be released soon. In contrast, the current version
of the Abbott assay accurately quantiﬁes HCV RNA whatever the
genotype [16,17]. Another assay, developed by Siemens Medical10 vol. 52 j 783–785
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Solutions Diagnostics (Tarrytown, New York) will become avail-
able soon.
Real-time PCR assays can detect and quantify minute amounts
of circulating HCV RNA. The Abbott assay has a lower limit of
detection and quantiﬁcation of 12 IU/ml. The ﬁrst-generation
CAP–CTM assay reports different types of results in the low
HCV RNA level range, including ‘‘undetectable” (undetermined
cutoff), ‘‘detectable but not quantiﬁable” (<15 IU/ml), or ‘‘quanti-
ﬁable” (>15 IU/ml). Importantly, HCV RNA levels between 15 and
43 IU/ml fall out of the linear range of quantiﬁcation of the assay,
and the manufacturer recommends interpreting the absolute
value with caution. Thus, the deﬁnition for ‘‘undetectable HCV
RNA” has changed with the implementation of real-time PCR
assays and this could have consequences in the way patients
are categorized for treatment decisions.
In the current issue of the Journal, Sarrazin et al. [18] reana-
lyzed stored serum samples from patients included in two large
international trials with the CAP–CTM assay. The patients had
been treated with pegylated IFN-a and various doses of ribavirin
for various durations. Originally, undetectable HCV RNA had been
deﬁned as an HCV RNA level below 50 IU/ml in the qualitative,
non-quantitative Cobas Amplicor™ assay. The authors could ret-
est baseline, week 4, week 12, end-of-treatment, and end-of-fol-
low-up samples from 164 out of the 1311 genotype 1-infected
patients included in the trial by Hadziyannis et al. [19], and week
4 samples from 135 out of the 1469 genotype 2- and 3-infected
patients included in the trial by Shiffman et al. [10]. We can con-
clude the following from their study: (1) at weeks 4, 12, and at
the end of treatment, the vast majority of patients with undetect-
able HCV RNA with the Cobas Amplicor™ assay (<50 IU/ml) also
have an HCV RNA level below the lower limit of quantiﬁcation of
the CAP–CTM assay (<15 IU/ml); (2) the lower limit of quantiﬁca-
tion in real-time PCR (15 IU/ml) can be used as a decision thresh-
old to deﬁne the rapid or (complete) early virological response
and make a decision to shorten therapy to 24 or 16 weeks in
genotype 1 or genotype 2–3 rapid virological responders, respec-
tively; (3) the patients with detectable but unquantiﬁable
(<15 IU/ml) HCV RNA at week 4 or 12 in CAP–CTM relapse more
often than those with truly undetectable HCV RNA at these time
points.
These results, although based on a relatively small number of
patients and retrospective, tend to indicate that, with pegylated
IFN-a and ribavirin therapy, the lower limits of quantiﬁcation
of the real-time PCR assays can be used for response-guided ther-
apy without altering the recommendations based on clinical tri-
als in which a threshold of 50 IU/ml was used. These ﬁndings
are not truly surprising if one realizes that the difference between
15 and 50 IU/ml is only 0.5 Log10 IU/ml, and given the lack of
accuracy of quantiﬁcation between 15 and 43 IU/ml in the ver-
sion of the CAP–CTM assay used in the study. They question
the meaning of the lower limit of detection of the CAP–CTM assay
relative to its lower limit of quantiﬁcation. The fact that a sub-
stantial number of patients with detectable but unquantiﬁable
HCV RNA at weeks 4 and 12 relapsed, whereas those with unde-
tectable HCV RNA in CAP–CTM did not, suggests that the latter
group has HCV RNA levels far below the lower limit of detection
of the assay at the time of determination. It is likely that these
patients became HCV RNA undetectable before week 4. In the
absence of available samples before this time point, the study
does not answer the question as to when the patients who
achieved an SVR lost detectable HCV RNA with the CAP–CTM
assay.784 Journal of Hepatology 201Chronic hepatitis C therapy is evolving and the current stan-
dard-of-care will soon be just a memory. The triple combination
of pegylated IFN-a, ribavirin, and a direct acting antiviral mole-
cule, initially a speciﬁc HCV protease inhibitor, will likely become
standard for treatment-naïve and non-responder patients within
a couple of years. The addition of a potent protease inhibitor con-
siderably accelerates the ﬁrst slope of viral decline during the
ﬁrst few days of therapy [20–22]. It might also impact the second
slope of viral decline, but this has not yet been witnessed, as the
majority of patients lose their HCV RNA early on therapy. Phase II
trials with pegylated IFN-a, ribavirin and telaprevir or boceprevir
have shown higher breakthrough and relapse rates in patients
who did not achieve an RVR at week 4, as assessed by real-time
PCR [23–25]. As a result, response-guided therapy has been
adopted in the design of the ongoing Phase III trials and no
patient with detectable HCV RNA at week 4 of therapy will
receive less than 48 weeks of therapy. However, a recent study
with telaprevir has shown that these patients represent less than
20% of those who are treated [26]. Thus, the vast majority of
patients receiving the triple combination achieve an RVR and
the ongoing trials will not establish the ideal treatment duration
in this group.
The key question with these new therapies will thus not be
whether or not the patients achieve an RVR at week 4, but when
they lose HCV RNA on treatment, and how this information can
be used to tailor the dose and duration of therapy. Unfortunately,
the question will not be answered by the ongoing Phase III trials.
Thus, as soon as the new drugs reach the market, it will be essen-
tial to conduct new prospective trials aimed at determining the
ideal time points for assessment of HCV RNA loss, assessing the
respective predictive values of on-treatment viral kinetics, and
pretreatment parameters (including recently identiﬁed genetic
markers of IFN response), and directing future procedures for
response-guided therapy. Because of their intrinsic characteris-
tics, in particular their analytical sensitivity, real-time PCR assays
are the ideal tools to address this issue. In this respect, the study
by Sarrazin et al. is just a prologue to a new season of an ‘‘HCV
virology in therapy” series.
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